In Q1 of fiscal 2025, the quarter ended Mar 31, 2025, Cell Source, Inc. used $600,391 of cash from operations, down 245.3% from the same quarter a year earlier.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Mar 31, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
Q2 FY2024
Jun 30, 2024
|
Q1 FY2024
Mar 31, 2024
|
Q4 FY2023
Dec 31, 2023
|
Q3 FY2023
Sep 30, 2023
|
Q2 FY2023
Jun 30, 2023
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Stock-based compensation |
—
|
—
|
—
|
0
|
0
|
—
|
—
|
—
|
—
|
| Operating cash flow |
-3
-40.6%
|
-1
-245.3%
|
-1
-3.6%
|
-1
-128.2%
|
-1
-8.4%
|
-0
+43.8%
|
-1
+0.1%
|
-0
+74.2%
|
-1
-244.7%
|
| Financing | |||||||||
| Short-term debt issued |
—
|
—
|
0
|
0
|
—
|
—
|
—
|
—
|
—
|
| Financing cash flow |
3
+49.7%
|
1
+247.5%
|
1
+7.8%
|
1
+119.3%
|
1
+31.2%
|
0
-31.0%
|
1
-15.7%
|
0
-77.3%
|
1
+440.4%
|
| Change in cash | |||||||||
| Net change in cash |
0
+100.9%
|
-0
-230.9%
|
0
+163.2%
|
-0
-248.0%
|
0
+181.5%
|
-0
+75.3%
|
0
-87.5%
|
-0
-130.6%
|
-0
+14.2%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLCS (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1569340
- Former names
- TICKET TO SEE, INC. (until Jun 26, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.